H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $90 from $85 and keeps a Buy rating on the shares. The firm says Elektrofi bring a complementary platform and adds a second royalty growth engine with 2040s durability.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Nike reports Q1 beat, U.S. takes 5% stake in Lithium Americas: Morning Buzz
- Halozyme Acquires Elektrofi to Enhance Drug Delivery
- Halozyme backs FY25 adjusted EPS view $6.00-$6.40, consensus $6.05
- Halozyme sees Elektrofi deal less than 5% dilutive to EPS over medium term
- Halozyme to acquire Elektrofi for upfront payment of $750M